| 2.82 -0.04 (-1.4%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.74 | 1-year : | 4.07 |
| Resists | First : | 3.2 | Second : | 3.49 |
| Pivot price | 2.97 |
|||
| Supports | First : | 2.75 | Second : | 2.28 |
| MAs | MA(5) : | 2.85 |
MA(20) : | 3.02 |
| MA(100) : | 2.84 |
MA(250) : | 3.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 20.7 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 4.55 | Low : | 2.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BLRX ] has closed above bottom band by 15.3%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.05 - 3.06 | 3.06 - 3.07 |
| Low: | 2.78 - 2.8 | 2.8 - 2.82 |
| Close: | 2.79 - 2.82 | 2.82 - 2.85 |
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Mon, 20 Jul 2026
Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy - Stock Titan
Fri, 17 Jul 2026
BioLineRx (BLRX) Q4 2024 earnings summary - Quartr
Thu, 25 Jun 2026
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 27 May 2026
BLRX: GLIX1 clinical trial launched for GBM, APHEXDA sales and royalties up, cash runway into 2027 - TradingView
Wed, 27 May 2026
BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX) - Yahoo Finance
Wed, 27 May 2026
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 137 (K) |
| Shares Short P.Month | 167 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.59 |
| Profit Margin | 0 % |
| Operating Margin | -629.8 % |
| Return on Assets (ttm) | -16.6 % |
| Return on Equity (ttm) | -46.8 % |
| Qtrly Rev. Growth | 87 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -2.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 8.76 |
| Price to Cash Flow | -1.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|